CONTEXT: Anorexia nervosa (AN), a state of chronic nutritional deprivation, is characterized by GH resistance with elevated GH levels and decreased levels of IGF-I. The effects of supraphysiological recombinant human GH (rhGH) on GH resistance in AN are not currently known. OBJECTIVE: The aim was to investigate whether supraphysiological rhGH increases IGF-I levels in AN. DESIGN AND SETTING: We conducted a randomized, placebo-controlled study in a Clinical Research Center. PATIENTS: We studied 21 women with AN, 10 (mean age, 28 ± 2.1 yr) treated with rhGH and 11 (mean age, 29.2 ± 2.6 yr) treated with placebo. INTERVENTIONS:rhGH (mean maximum daily dose, 1.4 ± 0.12 mg/d) or placebo was administered to patients for 12 wk. MAIN OUTCOME MEASURES: IGF-I, N-terminal propeptide of type 1 procollagen, type I collagen C-telopeptide, glucose, and insulin levels were measured at wk 0, 1, 2, 3, 4, 8, and 12; C-terminal propeptide of type 1 procollagen, leptin, and free fatty acid levels were measured at wk 0 and 12. Body composition, including total fat and lean mass, was measured by dual-energy x-ray absorptiometry at wk 0 and 12. RESULTS:IGF-I levels did not differ between the groups at baseline or after treatment (median after 12 wk-rhGH, 124 ng/ml, interquartile range, 94.5, 170.3; vs. placebo, 85.5 ng/ml, interquartile range, 62, 139; P = 0.3). Similarly, changes in glucose, insulin, free fatty acids, and bone markers did not differ between the groups. Total fat mass and percentage fat mass (rhGH, -2.5 ± 0.6%, vs. placebo, 2.2 ± 1.1%; P = 0.004) decreased significantly in the rhGH group compared to placebo despite comparable weight. CONCLUSIONS:Supraphysiological rhGH administration decreases fat mass in AN without increasing IGF-I levels, supporting the role of GH as a mediator of lipolysis independent of IGF-I.
RCT Entities:
CONTEXT: Anorexia nervosa (AN), a state of chronic nutritional deprivation, is characterized by GH resistance with elevated GH levels and decreased levels of IGF-I. The effects of supraphysiological recombinant human GH (rhGH) on GH resistance in AN are not currently known. OBJECTIVE: The aim was to investigate whether supraphysiological rhGH increases IGF-I levels in AN. DESIGN AND SETTING: We conducted a randomized, placebo-controlled study in a Clinical Research Center. PATIENTS: We studied 21 women with AN, 10 (mean age, 28 ± 2.1 yr) treated with rhGH and 11 (mean age, 29.2 ± 2.6 yr) treated with placebo. INTERVENTIONS: rhGH (mean maximum daily dose, 1.4 ± 0.12 mg/d) or placebo was administered to patients for 12 wk. MAIN OUTCOME MEASURES: IGF-I, N-terminal propeptide of type 1 procollagen, type I collagen C-telopeptide, glucose, and insulin levels were measured at wk 0, 1, 2, 3, 4, 8, and 12; C-terminal propeptide of type 1 procollagen, leptin, and free fatty acid levels were measured at wk 0 and 12. Body composition, including total fat and lean mass, was measured by dual-energy x-ray absorptiometry at wk 0 and 12. RESULTS:IGF-I levels did not differ between the groups at baseline or after treatment (median after 12 wk-rhGH, 124 ng/ml, interquartile range, 94.5, 170.3; vs. placebo, 85.5 ng/ml, interquartile range, 62, 139; P = 0.3). Similarly, changes in glucose, insulin, free fatty acids, and bone markers did not differ between the groups. Total fat mass and percentage fat mass (rhGH, -2.5 ± 0.6%, vs. placebo, 2.2 ± 1.1%; P = 0.004) decreased significantly in the rhGH group compared to placebo despite comparable weight. CONCLUSIONS: Supraphysiological rhGH administration decreases fat mass in AN without increasing IGF-I levels, supporting the role of GH as a mediator of lipolysis independent of IGF-I.
Authors: N Mauras; K O O'Brien; S Welch; A Rini; K Helgeson; N E Vieira; A L Yergey Journal: J Clin Endocrinol Metab Date: 2000-04 Impact factor: 5.958
Authors: S Grinspoon; E Thomas; S Pitts; E Gross; D Mickley; K Miller; D Herzog; A Klibanski Journal: Ann Intern Med Date: 2000-11-21 Impact factor: 25.391
Authors: K K Miller; S Grinspoon; S Gleysteen; K A Grieco; J Ciampa; J Breu; D B Herzog; A Klibanski Journal: J Clin Endocrinol Metab Date: 2004-09 Impact factor: 5.958
Authors: Corrine K Welt; Jean L Chan; John Bullen; Robyn Murphy; Patricia Smith; Alex M DePaoli; Aspasia Karalis; Christos S Mantzoros Journal: N Engl J Med Date: 2004-09-02 Impact factor: 91.245
Authors: Jennifer D Wallace; Winsome J Abbott-Johnson; Darrell H G Crawford; Ross Barnard; Julia M Potter; Ross C Cuneo Journal: J Clin Endocrinol Metab Date: 2002-06 Impact factor: 5.958
Authors: Alexander T Faje; Pouneh K Fazeli; Debra K Katzman; Karen K Miller; Anne Breggia; Clifford J Rosen; Nara Mendes; Anne Klibanski; Madhusmita Misra Journal: Bone Date: 2012-06-15 Impact factor: 4.398
Authors: Pouneh K Fazeli; Irene S Wang; Karen K Miller; David B Herzog; Madhusmita Misra; Hang Lee; Joel S Finkelstein; Mary L Bouxsein; Anne Klibanski Journal: J Clin Endocrinol Metab Date: 2014-01-23 Impact factor: 5.958
Authors: Annewieke W van den Beld; Olga D Carlson; Maire E Doyle; Dimitris Rizopoulos; Luigi Ferrucci; Aart Jan van der Lely; Josephine M Egan Journal: Eur J Endocrinol Date: 2019-02-01 Impact factor: 6.664